• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconValeant Pharmaceuticals

Valeant Pharmaceuticals

I Dont Want To Get Rid Of My Psoriasis
HealthValeant Stock Was Having a Pretty Good 2018—Until Today
By Sy MukherjeeJune 18, 2018
Cosmopolitan: Let's Talk About It Event
FinanceValeant Is Paying to Get Rid of Its $1 Billion ‘Female Viagra’ Acquisition
By Jen WiecznerNovember 6, 2017
Former Turing Pharmaceuticals CEO Martin Shkreli Case Nears End As Lawyers Prepare For Final Argument
TechA New ICO Wants to Get That Wu-Tang Album Out of Martin Shkreli’s Hands
By David Z. MorrisSeptember 25, 2017
FinanceJoe Biden Spars With Bill Ackman
By David Z. MorrisJune 24, 2017
Bill Ackman herbalife
FinanceBill Ackman Lost $7.7 Million Per Day on Valeant Stock
By Jen WiecznerMarch 15, 2017
Trading At The NYSE As Valeant Shares Halted Ahead of News Announcement
FinanceValeant’s Debt Refinance Will Go On Without Bill Ackman
By ReutersMarch 14, 2017
Ackman, founder and CEO of hedge fund Pershing Square Capital Management, speaks to audience in New York
FinanceBill Ackman’s Valeant Exit Is an Enormous Loss for the Faded Hedge Fund Star
By Stephen GandelMarch 13, 2017
Squawk Box - Season 20
HealthThis Investor Says Hedge Funds’ Bets on Valeant Were Worse Than Enron
By Sy MukherjeeNovember 16, 2016
Valeant Pharmaceuticals Offices Ahead Of Earnings Figures
HealthValeant Is Being Sued Over the ‘Female Viagra’ Pill
By Reuters and Tekendra ParmarNovember 2, 2016
Valeant Pharmaceuticals Offices Ahead Of Earnings Figures
FinanceValeant Is Said to Be Hiring This Zoetis Exec as Its New CFO
By Reuters and Michelle TohAugust 22, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
HealthT. Rowe Price Sues Valeant Over Alleged Fraud
By Sy MukherjeeAugust 18, 2016
Valeant Pharmaceuticals International Inc. Executives Testify At Senate Hearing On Drug Prices
FinanceValeant’s Troubles Aren’t Driving It To Lower Drug Prices
By Jen WiecznerAugust 9, 2016
The headquarters of Valeant Pharmaceuticals International, Inc. stands in Bridgewater Township, U.S., on Wednesday Nov. 04, 2015. Photographer: Michael Nagle/Bloomberg
HealthNew Valeant CEO Meets Investors Amid Company Struggles
By ReutersJune 14, 2016
FeaturesYellen Speaks, California Votes, and Valeant Reports—5 Things to Look For in the Week Ahead
By Tom Huddleston Jr.June 5, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
FinanceValeant’s Former CEO Will Stay on as an $83,000-a-Month Consultant
By Lucinda ShenMay 31, 2016
1
  • 1
  • 2
  • 3
  • 4
4
Most Popular
Law
DOGE cancelled a $349,000 grant to replace a museum’s HVAC after ChatGPT flagged it as DEI, court documents showAn image of a popular article
By Fortune EditorsMarch 19, 2026
Economy
Social Security has 6 years left. The fix that sounds cruelest may be the smartestAn image of a popular article
By Fortune EditorsMarch 19, 2026
Economy
Gen Z’s straight‑A boom is quietly shrinking their paychecksAn image of a popular article
By Fortune EditorsMarch 19, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.